Signia Therapeutics is a spin-off of Université Claude Bernard Lyon1, that has and will continue to develop a proprietary platform to identify new products for the respiratory tract virus market where new approaches are greatly needed. Signia Therapeutics benefits from well established academic and industrial partnerships of VirPath laboratory, which contribute to significantly de-risking the path […]
Acute respiratory tract infection Acute respiratory tract infections (ARTI) represent the main cause of acute diseases worldwide and remain the number one cause of deaths in newborns and young children (nearly 2 million deaths/year). Respiratory pathogens represent a major public health issue and have a large socio-economic impact. ARTI caused by several viruses including influenza […]
To identify and repurpose rapidly, efficiently and at low cost already marketed drugs for new antiviral indication Signia Therapeutics initial strategy focuses on the identification and repurposing of already FDA-approved drugs for new antiviral indication. The Company’s proposes a novel strategy to identify and repurpose rapidly, efficiently and at low cost already marketed drugs for […]
President Michel Cousineau (MBA) has over 35 years of experience in corporate and business development in the health care sector for emerging companies as well as with subsidiaries of large international biopharmaceutical companies. He brings a vast network of contacts throughout the industry at various level of management and with investment groups. […]
It seems we can’t find what you’re looking for. Perhaps searching can help.